$GILD

Gilead Sciences introduces Bixlenvo, a once-daily HIV treatment pill combining lenacapavir and bictegravir. It targets adults with suppressed viral loads who need alternatives to existing single-tablet regimens, estimated at 5%+ of U.S. HIV patients. Priced at $4,595/month before discounts, it aims to expand treatment choices, not replace current options. Gilead offers assistance programs for uninsured and insured patients.

Gilead Sciences (GILD) received three FDA approvals in four months, boosting its stock 21% YTD. Recent approvals include Bixlenvo for HIV and Trodelvy for breast cancer. The company expects more approvals, including anito-cel for multiple myeloma by year-end. Gilead's Q2 revenue was $7.6B, up 8% YoY, with strong HIV drug sales. The company raised its dividend to $0.82, yielding 2.15%.

Gilead Sciences (GILD) is a large-cap biopharmaceutical company with a $185.9B market cap. Its stock is up 17.3% over the past three months, outperforming the S&P 500. GILD has gained 32.7% over the past 52 weeks, trading above its 200-day and 50-day moving averages. The FDA recently approved its Trodelvy drug for treating triple-negative breast cancer. Analysts rate GILD a 'Strong Buy' with a mean price target of $159.10, implying 6.3% upside.

Gilead Sciences (GILD) shares rose 13.6% since its last earnings report. Q2 2026 saw a narrower adjusted loss of $6.75 per share and revenue growth of 10% to $7.80 billion, driven by HIV portfolio and Trodelvy. GILD raised full-year HIV sales growth guidance to 9-10%.

O'Day Daniel Patrick (Chairman & CEO) sold 15,000 shares of GILEAD SCIENCES, INC. (GILD) at an average of $148.64 ($147.51–$149.38, $2.23M total) across 3 trades on 2026-09-01 under a Rule 10b5-1 trading plan.

Merck and Gilead Sciences are developing a weekly oral HIV treatment combining islatravir and lenacapavir, both FDA-approved separately. The combination aims to offer an alternative to daily HIV medication.

The FDA approved Gilead Sciences' Bixlenvo, a once-daily single-tablet HIV treatment for virologically suppressed adults. The drug combines bictegravir and lenacapavir, simplifying therapy and reducing pill burden. Clinical trials showed non-inferior viral suppression rates and improved health metrics. Bixlenvo is designed for patients with complex treatment histories or resistance challenges.

U.S. President Trump has secured drug-pricing deals with over 20 pharmaceutical companies, including Pfizer, Johnson & Johnson, and Novo Nordisk, to reduce prescription costs. Agreements involve 'most-favoured-nation' pricing, sales through TrumpRx.gov, and U.S. investment pledges in exchange for tariff relief. Companies like Pfizer and Novo Nordisk have committed to significant price reductions on specific drugs.

The FDA approved Gilead Sciences' once-daily HIV pill, Bixlenvo, for adults with suppressed HIV who cannot use current single-pill treatments. It combines bictegravir and lenacapavir, with a list price of $4,595 per month. Gilead aims to provide more treatment options, especially for older patients with complex regimens. According to the company, this group represents about 5% of HIV patients in the U.S.

President Trump announced new voluntary drug pricing agreements with nine pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Merck, to lower U.S. prescription drug prices. The deals, part of the TrumpRx platform, aim to align prices with those in other wealthy nations. Companies receive tariff relief in exchange for participation. Critics note limited impact on patient costs and lack of public contract details.